Clinical trials: Vascular
Macular Degeneration, Macular Edema
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone for the treatment of macular edema associated with branch retinal vein occlusion.
- Conditions
- Macular Degeneration, Macular Edema, Branch Retinal Vein Occlusion
- Trial name
- NCT00308477
- Testing
- dexamethasone
- Where
- 12 sites in Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Cerebral Hemorrhage, Head Injury
Biomarkers Correlation With Volemia
The purpose of this study is to determine whether the Biomarkers (pro adrenomedullin (MR proADM), pro arginin vasopressin (CT proAVP), pro atrial natriuretic peptid (MR proANP), Pro Endothelin) changes at Day 2, Day 5 and Day 7…
- Conditions
- Cerebral Hemorrhage, Head Injury, Non Traumatic Post Surgery, Poly Trauma Patients Without Heart Failure
- Trial name
- ENVOL (NCT01858675)
- Testing
- Biomarkers, red blood cells and plasma assessment
- Where
- France
- Volunteers
- 66 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07236801
- Testing
- YTS109 cell
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB203 PFS
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema
- Trial name
- NCT06708637
- Testing
- FYB203 2 mg (0.05 mL of 40 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Formycon AG
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT05024045
- Testing
- LOXO-338, Pirtobrutinib
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Asphyxia Neonatorum
Biomarkers And Neurological Outcome in Neonates 2
Follow-up of participants of BANON1 study at age of at least 2 years. BANON1 (ClinicalTrials.gov ID: NCT03357250): Validation of biomarkers based on 24 months neuro-developmental outcome data in a human population for their…
- Trial name
- BANON2 (NCT04714775)
- Where
- 13 sites in Germany, Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- InfanDx AG
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Chronic Wound
Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds
The study objectives are to evaluate safety and efficacy of topical administration of RPh201 oil solution (botanical extract) for treatment of patients with hard to heal chronic ulcerated wounds.
- Trial name
- NCT01429519
- Testing
- RPh201, botanical drug product
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Regenera Pharma Ltd
Acute Ischemic Stroke
Prospective, Multicentre Study to Evaluate the Thrombectomy System for Stroke: iNedit, iNdeep and iNtercept
First prospective, single-arm, multicentre study to evaluate the safety and efficacy of the overall stroke thrombectomy system: iNedit, iNdeep and iNtercept in patients with acute ischemic stroke.
- Trial name
- SEMTiC (NCT05893719)
- Testing
- iNedit, iNdeep, iNtercept
- Where
- 18 sites in Belgium, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- iVascular S.L.U.
Multiple Myeloma
Study of bb21217 in Multiple Myeloma
Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT03274219
- Testing
- bb21217
- Where
- 11 sites in United States
- Volunteers
- 72 people
- Sponsor
- 2seventy bio
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
- Trial name
- NCT05544019
- Testing
- SGR-1505
- Where
- 36 sites in United States, France and 6 more
- Volunteers
- 98 people
- Sponsor
- Schrödinger, Inc.
Hypertension
A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure
The main aim of this study is to check the safety of TAK-536. This study will take place in Japan. At the first visit, the study doctor will check if each child can take part.
- Trial name
- NCT04668157
- Testing
- TAK-536
- Where
- 19 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Takeda
Acute Myocardial Infarction, STEMI
Evaluation in STEMI Patients Using FDY-5301
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
- Conditions
- Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization
- Trial name
- IOCYTE AMI-3 (NCT04837001)
- Testing
- FDY-5301
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 2,351 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Multi Vessel Coronary Artery Disease
Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)
A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the XABG technology in patients with multi-vessel atherosclerotic coronary artery disease, scheduled by the…
- Trial name
- XABG FIH (NCT04545112)
- Testing
- CABG
- Where
- 4 sites in Belgium, Lithuania and 1 more
- Volunteers
- 20 people
- Sponsor
- Xeltis
Hypertension
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.
- Trial name
- NCT00779181
- Testing
- ADX415
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Sarcoma, Kaposi, HIV Infections
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in…
- Trial name
- NCT00002319
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- 33 sites in United States
- Sponsor
- Sequus Pharmaceuticals
Ocular Blood Flow
The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow
Objectives:To determine LYC-001e's influences on ocular blood flow Ocular blood flow has been implicated as a parameter relevant to eye health and involved in the disease process of several ophthalmic pathologies including AMD…
- Trial name
- NCT03068377
- Testing
- Experimental
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LycoRed Ltd.
AAA - Abdominal Aortic Aneurysm
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER®…
- Trial name
- NCT06218875
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 2,000 people
- Sponsor
- W.L.Gore & Associates
Stroke, Ischemic
Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients
This observational, prospective cohort, pilot study aims at investigating usability, operational, and economical factors around 'traditional' and 'technology-supported' approaches to promote a healthy life-style in stroke…
- Trial name
- NCT04733339
- Testing
- Secondary Prevention
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Cereneo AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.